In 2017, the CANTOS trial demonstrated that administration of an antibody directed against the pro-inflammatory cytokine interleukin-1β (IL-1β) reduced cardiovascular events in patients with coronary artery disease (CAD), thereby providing first evidence for effectiveness of an immunotherapy in CVD (14). Here, IL1B is linked to coronary artery disorder.